CIRCULATING TUMOUR CELLS

CTC (Circulating tumour cells) are carcinoma cells which have been separated from the carcinoma and they have entered the blood stream where they circulate and show a potential for development of metastatic deposits.
These cells can be isolated and identified, and as a result the interest in their detection has been growing exponentially due to:
- Early detection and establishment of a diagnosis of new carcinomas
- Monitoring the course of the disease of the existing carcinoma
- Prognosis – providing information about the risk of repeated appearance of the “old” carcinoma type which is currently present.
BIOMED AID offers general tests for discovery of CTC’s cells, along with tests for specific carcinoma types, including breast carcinoma, carcinoma of the large intestine, prostate carcinoma, malignant melanoma and sarcoma….

https://www.rgcc-group.com/

R.G.C.C. LABORATORIJA

R.G.C.C.is a Swiss company whose activity is working with medical genetics, in particular with the genetics of cancer (chemosensitivity and chemoresistance). The primary aim lies in the potential to provide access to most of the information which may be useful in the treatment for cancer patients who seek the best possible personalized and integrated treatment.

The tests are prepared in a simple manner, with peripheral blood samples of 20-40 ml.

The analysis is used to isolate the malignant cells, to determine the type of the cancer and the potential existence of metastatic cells. The severity of the disease is also determined on basis of the number of cells in ml units in the blood, along with the invasiveness of the disease.

Determining what the existing malignant cells are sensitive or resistant to is very important. The sensitivity and resistance shall be determined for all known medicaments and supplements.

BIOMED AID is a representative of the R.G.C.C. laboratories for the Balkan region.

 https://www.rgcc-group.com/ 

TESTS

BIOMED AID offers general tests for discovery of CTC’s cells, along with tests for specific carcinoma types, including breast carcinoma, carcinoma of the large intestine, prostate carcinoma, malignant melanoma and sarcoma….
These tests permit:
1. Detection of early signs of carcinoma in formation.
2. Aid for monitoring of the existing carcinomas.
3. Preparation of an individual profile and about the medications which can be used to treat the carcinoma, and therapeutic methods and natural substances which can be used to obtain the best possible effects from the treatment.
A qualitative analysis shall also be prepared, particularly with a percentual testing of the sensitivity of the medications and the therapy for treatment of the carcinoma, such as: Cytostatics, radiotherapy, onco-hyperthermia, monoclonal antibodies, supplements….

Onconomics

Sensitivity of cytostatics.
Provide information about the effect of individual medications on the carcinoma cells of the patient.

Onconomics Plus

Detection of the sensitivity to cytostatics, targeted therapies (monoclonal antibodies and inhibitors) and natural substances.
This test covers the information provided with the Onconomics test. Furthermore, this test also includes an assessment of the effectiveness of the natural biological substances and natural extracts on the malignant cells.

Onconomics Extracts

Examination of the sensitivity exclusively for the natural substances.
Provide information about the effectiveness of natural biological substances or extracts on the malignant cells.

MONITORING TESTS
Oncocount

Determining the number of CTC cells.
Provide information only with regards to the presence and the concentration of circulating tumour cells.

Oncotrail

Determining the number of CTC cells and immunophenotypes for certain specific types of malignant diseases.
This test is an example of customized tests for specific types of malignant disease such as breast carcinoma and prostate carcinoma. This test only contains markers which are relevant for a specific type of malignant diseases which in turn make this test an excellent tool for controlled monitoring of the course of the disease.

Oncotrace

Determining the number of CTC cells and immunophenotypes for all types of malignant diseases.
This test provides information about the presence of circulating tumor cells, their concentration and their immunophenotype.

en_USEnglish
Share This